Updates are available Correction dated 2025-06-30
Click to view Correction: https://doi.org/10.1038/s41409-025-02664-5
-
Authors
Bekadja, Mohamed Amine
Niederwieser, Dietger https://orcid.org/0000-0002-4737-1103
Kharfan-Dabaja, Mohamed A. https://orcid.org/0000-0001-7394-5185
El Fakih, Riad
Garderet, Laurent
Yakoub-Agha, Ibrahim https://orcid.org/0000-0003-4524-8782
Greinix, Hildegard https://orcid.org/0000-0002-2780-3300
Weisdorf, Daniel J. https://orcid.org/0000-0001-8078-8579
Galeano, Sebastian
Ahmed, Syed Osman
Chabanon, Christian https://orcid.org/0000-0002-3755-4889
Hashmi, Shahrukh K. https://orcid.org/0000-0002-8914-7927
Ruggeri, Annalisa https://orcid.org/0000-0002-7261-2765
Gergis, Usama https://orcid.org/0000-0003-0656-7385
Bazarbachi, Ali https://orcid.org/0000-0002-7171-4997
Hamad, Nada https://orcid.org/0000-0001-7929-1450
Albeihany, Amal
Pasquini, Marcelo https://orcid.org/0000-0003-1579-2293
Hanbali, Amr
Szer, Jeff https://orcid.org/0000-0001-6783-2301
Kodera, Yoshihisa
Kumar, Ambuj
Elhassan, Tusneem
McLornan, Donal https://orcid.org/0000-0003-1224-091X
Worel, Nina https://orcid.org/0000-0002-3599-8099
Greco, Raffaella https://orcid.org/0000-0002-6117-5328
Mohty, Mohamad https://orcid.org/0000-0002-7264-808X
Atsuta, Yoshiko https://orcid.org/0000-0003-4404-2870
Koh, Mickey https://orcid.org/0000-0002-4368-2502
Sureda, Anna https://orcid.org/0000-0002-1238-6970
Rondelli, Damiano
Aljurf, Mahmoud https://orcid.org/0000-0003-3942-7370
Rasheed, Walid
- License Information
-
More Information
Article History
Received: 6 August 2024
Revised: 24 September 2024
Accepted: 26 September 2024
First Online: 7 October 2024
Change Date: 24 June 2025
Change Type: Update
Change Details: The original online version of this article was revised: In this article the author name Dietger Niederwiser has been corrected to Dietger Niederwieser and fig. 3 replaced.
Change Date: 30 June 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41409-025-02664-5
Competing interests
: MAB, DN, REF, DJW, SG, AR, AB, AH, YK, AK, TE, MM, WR declare no conflicts of interest MAK-D: declares research/grant from Bristol Myers Squibb, Novartis, and Pharmacyclics, and lecture/honoraria from Kite Pharma; LG: declares relationship with Bristol Myers Squibb, Sanofi, Janssen, Pfizer; IY-A: declares honoraria from Kite Pharma, Novartis and Bristol Myers Squibb; HG: declares speaker bureau and consultancy for Therakos, Gilead, Novartis, Stemline, Neovii, Sanofi, and Takeda; SOA: declares advisory board with Kite Pharma and Novartis, and speaker honoraria from Kite Pharma, Novartis, and Johnson & Johnson; CC: declares honoraria (personal and institutional) for lectures and advisory boards from Bristol Myers Squibb, Kite Pharma/Gilead, Janssen, Jazz, Novartis, and Miltenyi Biotec; SKH: declares educational/travel grants from Novartis, Pfizer, Janssen, Therakos, Vertex, MSD, Roche; UG: declares consultancy/Honoraria :Kite Pharma, Incyte, Astellas, Jazz,and Vor; NH: honoria from Janssen, Novartis, Takeda, Abbvie, Roche, Astellas, Bigene; AA: declares lecture-Advisor /honoraria from Kite Pharma, Novartis, Takeda and Janssen; MP: declares research with Bristol Myers Squibb, Janssen, Kite Pharma, Novartis, and consultancy for Bristol Myers Squibb, Novartis, and honoraria from Gilead; JS: declares consultancy for Sanofi and ADRx, honoraria from Sanofi, Alexion, AstraZeneca Rare Disease, Prevail Therapeutics (Eli–Lilly), Pfizer, Sobi Pharmaceuticals, and Novartis, advisory committees for Sanofi, AstraZeneca Rare Disease, Prevail Therapeutics (Eli–Lilly), Pfizer, Sobi Pharmaceuticals, Novartis, speaker bureau for Sanofi, AstraZeneca Rare Disease, Prevail Therapeutics (Eli–Lilly), Pfizer, Sobi Pharmaceuticals, Novartis; DMc: declares lecture/honoraria from GSK, Novartis, Abbvie. Research funding from Imago Biosciences; NW: declares speakers fees from BMS Celgene, Kite Gilead, Novartis, Pierre Fabre, Sanofi Genzyme, Therakos Mallinckrodt, Travel reimbursement from Jannsen, Pierre Fabre; RG: declares speaking honoraria from Biotest, Pfizer, Medac, Neovii and Magenta; YA: declares lecture/honoraria from Otsuka Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co., Ltd., Novartis Pharma KK, Meiji Seika Pharma Co., Ltd, Janssen Pharmaceutical K.K., and consultancy fee from JCR Pharmaceuticals Co., Ltd and Kyowa Kirin Co., Ltd; MK: declares non-specified relationship with Kite Pharma, Takeda and Gilead; AS: declares honoraria from Takeda, Bristol Myers Squibb /Celgene, MSD, Janssen, Amgen, Novartis, Gilead Kite, Sanofi, Roche, Genmab, AbbVie, Jazz Pharmaceuticals, consultancy from Takeda, Bristol Myers Squibb/Celgene, Novartis, Janssen, Gilead, Sanofi, Genmab, AbbVie, speaker bureau for Takeda and Research support from Takeda; MA: declares lecture/honoraria from Kite Pharma and Vertex Pharma.
